by Raul Lopez | Nov 8, 2024 | blog
Updated September 2026. This article is educational and is not medical or legal advice.
Psychedelic culture has a talent for turning an interesting observation into a religion by Tuesday. OCD is defined by intrusive thoughts and compulsive behavior, so a treatment that temporarily loosens rigid cognitive patterns is an obvious research target. The clinical evidence is still preliminary and should not be confused with proof that one intense experience can “reset” OCD.
Risk, screening and context
Small early studies of psilocybin in OCD generated interest but do not provide the evidence depth seen in established exposure and response prevention therapy. A dramatic mechanism is still only a mechanism; it does not automatically prove a benefit, a risk or a cosmic interpretation.
Who gets screened out matters
OCD symptoms can fluctuate, and expectancy is especially hard to control in psychedelic trials. The temptation to universalize is understandable. Human beings encounter one enormous experience and immediately start writing laws for the cosmos.
The less glamorous safety questions
A meaningful subjective experience may matter, but symptom change needs validated measures and durable follow-up. The useful boundary is not between wonder and skepticism; it is between a claim we can inspect and a story we merely enjoy repeating.
What the studies do not prove
People with OCD should not stop evidence-based medication or therapy to conduct an uncontrolled experiment because a mechanism sounds elegant. There is no need to sand the mystery out of the subject. We can keep the mystery and stop pretending it already came with footnotes.
A better question is not “is this real?” but “which part is real in which sense?” Biology, subjective experience, law and culture can all be real while telling different stories about the same object.
The grown-up version
The grown-up position is not “believe everything” or “dismiss everything.” It is to follow the evidence as far as it goes, notice where culture takes over, and resist the urge to fill every blank space with certainty.
The companion article is Psychedelics and Virtual Reality: Therapy Tool or Expensive Screensaver?.
From evidence to imagery
The research belongs in the paragraph above; the artwork belongs over here. Keeping those roles separate is intentional. Browse Psychonaut art & clothing, the psychedelic journals and notebooks collection, or see Psychedelic Research Volunteer T-shirt.
Sources and further reading
by Raul Lopez | Nov 2, 2024 | blog
The subject is stranger than the headline and usually less magical than the marketing. Meditation and psychedelics can both destabilize the ordinary sense of self, amplify attention and produce experiences people call nondual or mystical. That does not make a mushroom a meditation retreat in capsule form or meditation a slow-motion drug.
Why the symbol refuses to die
Meditation is a trained attentional practice; psychedelic effects are pharmacologically induced and less voluntarily steerable. The boring caveat is often the important bit: who was studied, under what conditions, compared with what, and for how long?
What history does to a good myth
Both can alter self-referential processing and emotional salience, which may explain overlapping language. If that sounds less cinematic, good. Cinema has editors. Biology, law and human psychology are rarely so considerate.
Why the idea stuck
Practice can provide skills for observing difficult experiences, while psychedelics can overwhelm those skills rather than reward them. One study can move a question forward without settling it. Psychedelic headlines occasionally struggle with this modest concept.
The cultural residue
The cultural temptation is to use one path to certify the other; the more interesting approach is to study where they overlap and where they clearly do not. The real signal is easier to see once “promising,” “proven” and “possible” stop being treated as synonyms.
The larger pattern is less tidy than the usual headline but more informative. Different mechanisms, settings and people produce different outcomes, and a serious account has to make room for that variability.
The useful uncertainty
Uncertainty is not a failure state. It is information. Knowing exactly where the evidence thins out is often more valuable than another confident paragraph pretending the map continues past the edge.
From here, the obvious rabbit hole is Psychedelic Integration: What It Is and Why the Aftermath Matters.
The studio detour
The theory is one thing. The visual residue it leaves in psychedelic art is another, and frankly much easier to hang on a wall. Browse Meditation & spirituality art, the psychedelic T-shirts collection, or see Meditating With Psychedelics T-shirt.
by Raul Lopez | Oct 30, 2024 | blog
Updated September 2026. This article is educational and is not medical or legal advice.
Psychedelic research has unusual ethical pressure points: altered suggestibility, intense therapist relationships, functional unblinding, vulnerable participants and a media environment desperate for breakthroughs. Good intentions are not a substitute for safeguards.
The gap between a trial and a treatment
Participants may be unusually emotionally open during sessions, increasing the importance of boundaries, consent and independent reporting channels. If that sounds less cinematic, good. Cinema has editors. Biology, law and human psychology are rarely so considerate.
Where benefit meets uncertainty
Therapist effects and expectancy can influence outcomes while being difficult to separate from drug effects. One study can move a question forward without settling it. Psychedelic headlines occasionally struggle with this modest concept.
What comes next without the victory lap
Indigenous knowledge and communities can be cited as cultural ancestors while receiving little benefit from commercialization. The real signal is easier to see once “promising,” “proven” and “possible” stop being treated as synonyms.
What patients in trials actually received
Hype itself is an ethical variable because people make treatment decisions based on the story a field tells about its certainty. Interest survives uncertainty just fine. In fact, most of the genuinely interesting questions begin after the certainty has been removed.
What matters most is proportion. Big experiences do not automatically justify big claims, and small studies do not become useless merely because they cannot answer everything.
No cosmic receipt required
A subject can matter without proving a universal theory of consciousness, curing modern life or revealing what the universe “really” is. Sometimes the honest conclusion is narrower—and much more useful.
The next useful comparison is Psychedelic-Assisted Therapy for PTSD: Where the Evidence Stands.
The studio version of the idea
Nothing in the shop is medical advice, which is fortunate because T-shirts have a terrible record in peer review. The commercial connection here is visual culture, not treatment. Browse Psychonaut art & clothing, the psychedelic T-shirts collection, or see Psychedelic Research Volunteer T-shirt.
Sources and further reading
by Raul Lopez | Oct 25, 2024 | blog
Updated September 2026. This article is educational and is not medical or legal advice.
The subject is stranger than the headline and usually less magical than the marketing. Pain is biological, psychological and contextual at the same time, which makes psychedelics scientifically interesting without requiring mystical explanations. Early research asks whether changing attention, affect and meaning can change suffering even when tissue pathology does not vanish.
Who gets screened out matters
Pain intensity and pain unpleasantness are related but separable experiences, and treatments can affect them differently. There are real questions here. They become easier to see once the promotional fog and psychedelic folklore are moved out of the way.
The less glamorous safety questions
Psychedelic studies in chronic pain remain early compared with depression research. The strongest version of the idea is usually the one that needs the fewest miracles to stay standing.
What the studies do not prove
Changes in mood, fear, catastrophizing or body perception could plausibly influence pain outcomes without implying the pain was “all in someone’s head.” There is a difference between respecting an experience and accepting every explanation attached to it. We can manage both.
Promising is not the same as approved
People with chronic pain deserve better than being sold another miracle before comparative trials establish what helps, for whom and for how long. Anecdotes can point toward a question, but they cannot do the statistical heavy lifting simply because the anecdote is spectacular.
What survives scrutiny is still worth discussing. What does not survive can be retired without mourning; there will be no shortage of strange material left over.
Keep the weird, lose the nonsense
Skepticism is not the enemy of psychedelic culture; bad certainty is. The better approach is to keep the curiosity, keep the difficult questions and stop asking a beautiful story to impersonate a settled fact.
A related piece worth opening next is Psychedelics and OCD: What the Research Can—and Cannot—Tell Us.
The cultural afterimage
A clinical or legal question should end with evidence, not a sales pitch. For readers interested in how the subject appears in psychedelic visual culture, these are the relevant studio links. Browse Psychonaut art & clothing, the psychedelic art posters collection, or see The Psychonaut poster.
Sources and further reading
by Raul Lopez | Oct 24, 2024 | blog
Updated September 2026. This article is educational and is not medical or legal advice.
Psychedelic culture has a talent for turning an interesting observation into a religion by Tuesday. Eating disorders involve identity, reward, anxiety, body image and rigid behavior—domains psychedelics can certainly disrupt. That makes the research plausible and also makes overselling especially dangerous in a population with meaningful medical risk.
What patients in trials actually received
Current evidence is early and much smaller than the research base for depression. Anecdotes can point toward a question, but they cannot do the statistical heavy lifting simply because the anecdote is spectacular.
The comparison group problem
Eating disorders can involve cardiovascular, electrolyte and nutritional complications that change medical risk and require specialist care. The sensible version leaves enough room for both fascination and the possibility that the first explanation is wrong.
How strong is the signal?
A dramatic shift in self-perception may feel therapeutic without automatically changing entrenched eating-disorder behavior. A dramatic mechanism is still only a mechanism; it does not automatically prove a benefit, a risk or a cosmic interpretation.
Where this leaves the field
Any future psychedelic treatment will need to integrate medical stabilization, evidence-based psychotherapy and long-term follow-up rather than becoming a replacement for them. The temptation to universalize is understandable. Human beings encounter one enormous experience and immediately start writing laws for the cosmos.
That is the version worth keeping: specific enough to be challenged, flexible enough to absorb new evidence and weird enough that nobody needs to manufacture extra mystery.
The grown-up version
The grown-up position is not “believe everything” or “dismiss everything.” It is to follow the evidence as far as it goes, notice where culture takes over, and resist the urge to fill every blank space with certainty.
If this raised another question, try Psychedelics and Chronic Pain: Why the Mind-Body Split Was Always Suspicious.
Where the science ends and the art starts
The science does not become stronger because there is art about it. The art does, however, show how these ideas escape the laboratory and enter culture. Browse Psychonaut art & clothing, the psychedelic journals and notebooks collection, or see The Psychonaut poster.
Sources and further reading
by Raul Lopez | Oct 22, 2024 | blog
Updated September 2026. This article is educational and is not medical or legal advice.
Here is the useful version, without the incense-cloud certainty: The future of psychedelic medicine will probably be less like a revolution and more like healthcare: specific drugs for specific indications, training rules, insurance fights, safety monitoring, failed products, useful products and paperwork. In other words, adulthood.
How strong is the signal?
FDA’s 2026 guidance signals that psychedelic drug development is being treated as a serious regulatory category with unusual trial-design challenges. The practical question is what this changes for the reader, not whether it can be made to sound profound in a caption.
Where this leaves the field
Psilocybin, MDMA-related programs, LSD formulations and non-hallucinogenic analogues are moving through different development paths rather than one unified “psychedelic approval.” What people report matters, but reports and controlled evidence answer different questions and should not be forced into the same box.
What follow-up tells us
Delivery models may determine access as much as drug efficacy because supported sessions can require hours of professional time. This is a good place to resist the psychedelic tendency to promote every interesting correlation to the rank of revelation.
Why setting is part of the intervention
The winners may be treatments that are not the most mystical, but the ones that demonstrate repeatable benefit, manageable risk and a healthcare model that can actually function. The internet prefers a revelation. Reality is usually messier, slower and considerably less interested in providing a satisfying headline.
If there is a theme running through the research and the culture, it is that simple stories travel farther than accurate ones. This page is trying to reverse that order.
The bit worth remembering
The strongest takeaway is not a slogan. It is a boundary: what we know, what we suspect, what people report and what culture has layered on top. Once those are separated, the subject gets clearer without becoming dull.
The next stop in this cluster is Psychedelic-Assisted Therapy for Eating Disorders: Early Signals, Hard Questions.
From evidence to imagery
If your interest is aesthetic rather than medical, the studio has taken the same subject in a considerably less clinical direction. Browse Psychonaut art & clothing, the psychedelic T-shirts collection, or see Psychedelic Research Volunteer T-shirt.
Sources and further reading
